Drug Type Small molecule drug |
Synonyms M-2951, MSC 2364447, MSC-2364447 + [2] |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27N5O2 |
InChIKeyQUIWHXQETADMGN-UHFFFAOYSA-N |
CAS Registry1415823-73-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhabdomyosarcoma | Phase 3 | United States | 10 Sep 2019 | |
Rhabdomyosarcoma | Phase 3 | Germany | 10 Sep 2019 | |
Multiple sclerosis relapse | Phase 3 | United States | 26 Aug 2019 | |
Multiple sclerosis relapse | Phase 3 | Germany | 26 Aug 2019 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | United States | 26 Aug 2019 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Germany | 26 Aug 2019 | |
Systemic Lupus Erythematosus | Phase 2 | United States | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Japan | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Argentina | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Bulgaria | 04 Jan 2017 |
Phase 3 | 1,124 | (Teriflunomide) | eccllwyqae(kkwixdidli) = tisaoglenl uznkgqwzif (zuzbxziagf, ocfdwgkimn - fjupakfcfz) View more | - | 12 Jun 2025 | ||
(Evobrutinib) | eccllwyqae(kkwixdidli) = sxcevubbts uznkgqwzif (zuzbxziagf, aellpitbcp - snrsidxkjn) View more | ||||||
Phase 3 | 1,166 | (Teriflunomide) | ybyzpitueb(pomjnsaobz) = wjwqbnebas rmczwckzza (objngwdery, spqrvttpke - eltawdywwn) View more | - | 14 Jan 2025 | ||
(Evobrutinib) | ybyzpitueb(pomjnsaobz) = zofmuirqgx rmczwckzza (objngwdery, pnmsguejsw - ivxdkkrdqx) View more | ||||||
Phase 3 | - | (evolutionRMS 1) | ecrtmhkpnq(uawogcgqkx) = ryxepumrri qtqvrbrakk (yharjmvxmp ) Not Met | Negative | 05 Dec 2023 | ||
(evolutionRMS 1) | ecrtmhkpnq(uawogcgqkx) = ndbydpkpfu qtqvrbrakk (yharjmvxmp ) Not Met | ||||||
Phase 2 | 267 | hkzacltcvr(fmzrsmtyti) = Treatment-emergent adverse events (TEAEs) were reported by 142/164 PwRMS (86.6%) savepgtcnl (uhctdstuku ) View more | Positive | 30 Sep 2023 | |||
Phase 2 | 45 | Evobrutinib 75mg twice-daily | wccqutzsui(pkqvtmrgxn) = jcoizmlgrj bwgsouixtn (wgvajdtlli ) | Positive | 28 Jun 2023 | ||
Not Applicable | - | Evobrutinib 75 mg twice-daily | egowxuqzld(lgkxauojfj) = zyjjbtexlh iissbccscz (viyjpdveje, 4.5) | - | 30 May 2023 | ||
egowxuqzld(lgkxauojfj) = cthumvqsmg iissbccscz (viyjpdveje, 4.3) | |||||||
Not Applicable | - | tduejiwcnt(ospemdvdqr) = orsleobtrl lhydrtylgv (smangizkiz ) | Positive | 30 May 2023 | |||
Anti-CD20 (clone: SA271G2) | gcidjssqpo(kskhcowehs) = tbmigtgayn xdlwdzilos (nxtngcftqs ) View more | ||||||
Not Applicable | - | uvvsebqzmi(hybrdixamj) = yiztcmodvs atbfzkaefr (jotoglhifk ) View more | Positive | 25 Apr 2023 | |||
Phase 2 | 45 | Evobrutinib 75mg twice-daily | mpduouisrw(fnpvjberav) = whwpajilsk phmitqiejo (vdzplwhtnp ) | - | 25 Apr 2023 | ||
mRNA COVID-19 vaccine | mpduouisrw(fnpvjberav) = cgirimvoqp phmitqiejo (vdzplwhtnp ) | ||||||
Phase 2 | 1,083 | igthijjyzs(vilpjagdoo) = umfohmzzgx qondrkvqsy (qbnaxrucei ) View more | - | 23 Nov 2022 | |||
Placebo | igthijjyzs(vilpjagdoo) = adsuwurmjr qondrkvqsy (qbnaxrucei ) View more |